Salarius Pharmaceuticals Files 8-K

TL;DR

Salarius Pharma filed an 8-K on Oct 10th, check financials.

AI Summary

Salarius Pharmaceuticals, Inc. filed an 8-K on October 14, 2025, reporting other events and financial statements as of October 10, 2025. The company, formerly known as Flex Pharma, Inc., is based in Houston, Texas.

Why It Matters

This filing indicates Salarius Pharmaceuticals is making official disclosures regarding its corporate activities and financial status to the SEC.

Risk Assessment

Risk Level: low — This is a routine filing of corporate information and does not inherently present new risks.

Key Players & Entities

• Salarius Pharmaceuticals, Inc. (company) — Registrant
• Flex Pharma, Inc. (company) — Former company name
• October 10, 2025 (date) — Date of earliest event reported
• October 14, 2025 (date) — Date of report
• Houston, TX (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 SLRX The Nasdaq Capital Market Indi

Filing Documents

• flks-20251010.htm (8-K) — 30KB
• a101325slrxregainsnasdaqco.htm (EX-99.1) — 16KB
• image_0.jpg (GRAPHIC) — 11KB
• 0001615219-25-000145.txt ( ) — 181KB
• flks-20251010.xsd (EX-101.SCH) — 2KB
• flks-20251010_lab.xml (EX-101.LAB) — 22KB
• flks-20251010_pre.xml (EX-101.PRE) — 13KB
• flks-20251010_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events On October 10, 2025, Salarius Pharmaceuticals, Inc. ("Salarius") received a letter from the Nasdaq Hearings Panel (the "Hearings Panel") of The Nasdaq Stock Market LLC ("Nasdaq") notifying Salarius that it has regained compliance with the minimum stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) (the "Equity Standard"), as required by the Hearings Panel. Nasdaq further notified Salarius that it will be subject to a Mandatory Panel Monitor for a period of one year from October 10, 2025. If, within that one-year monitoring period, the Listing Qualifications Staff (the "Staff") finds Salarius again out of compliance with the Equity Standard that was the subject of the exception, Salarius will not be permitted to provide the Staff with a plan of compliance with respect to that deficiency and the Staff will not be permitted to grant additional time for Salarius to regain compliance with respect to that deficiency, nor will the company be afforded an applicable cure or compliance period pursuant to Nasdaq Listing Rule 5810(c)(3). Instead, the Staff will issue a delisting determination letter and Salarius will have the opportunity to request a hearing with the Hearings Panel. On October 13, 2025, Salarius issued a press release announcing that that it had regained compliance with the Equity Standard. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of Salarius Pharmaceuticals, Inc., dated October 13, 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SALARIUS PHARMACEUTICALS, INC. Date: October 14, 2025 By: /s/ Mark J. Rosenblum Mark J. Rosenblum Acting Chief Executive Officer Executive Vice President & Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR